SGLT2 Receptor Inhibitor Therapeutics for Patients with Cardio-Renal-Metabolic Disorders: The Pharmacist’s Role

SGLT2 Receptor Inhibitor Therapeutics for Patients with
Cardio-Renal-Metabolic Disorders: The Pharmacist’s Role

CPE Midday Symposium at the 2021 ASHP Midyear Clinical Meeting

Date

Wednesday, December 8th, 2021
1:00 pm – 2:30 pm Eastern Time

Location

Virtual, Live Streamed Program
Register Below

**To view this CPE lecture beginning on Wednesday, December 8th at 1:00 pm ET, visit: https://us02web.zoom.us/j/82996569434

Date/Time

Wednesday, December 8th, 2021
1:00 pm – 2:30 pm Eastern Time

Location

Virtual, Live Streamed Program

Program Overview 

Recent clinical trials link cardiovascular, metabolic, and renal diseases, challenging the traditional clinician roles in healthcare. Optimal patient care now requires a shared responsibility of medication management between primary care practitioners, cardiologists, endocrinologists, and nephrologists. Pharmacists are uniquely poised to oversee and intervene on medication selection, dosing, and monitoring of patient outcomes. Our program will identify the connections of diabetes-heart failure-kidney disease while exploring the role pharmacists can play in optimizing new therapies.

Agenda

I. The Interconnection of Cardio-Renal-Metabolic Disorders and the Science of SGLT2 Receptor Inhibitors – John Fanikos, RPh, MBA

II. Clinical Trial Update for SGLT2i Therapeutics Targeting Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease – Leo Buckley, PharmD

III. The Pharmacist’s Role in the Application of SGLT2 Receptor Inhibitors to Manage T2D, Reducing Hospital Admissions for HF, Reducing CVD Deaths, and Slowing the Progression of CKD, Especially in the Pandemic Era of COVID-19 – Craig Beavers, PharmD

IV. Interactive Expert Panel Discussion – John Fanikos, RPh, MBA and Expert Faculty

Educational Objectives

  1. Understand the interconnection of cardio-renal-metabolic disorders and the science of SGLT2 receptor inhibitors
  2. Analyze recent clinical trial data for SGLT2i therapeutics targeting type 2 diabetes, heart failure, and chronic kidney disease
  3. Review the optimal role of pharmacists in the applications of SGLT2 receptor inhibitors to manage type 2 diabetes, reduce hospital admissions for heart failure, reduce cardiovascular deaths, and slowing the progression of chronic kidney disease, especially in the pandemic era of COVID-19

Chair

John Fanikos, RPh, MBA
Assistant Professor of Clinical Pharmacy Practice
Northeastern University
Massachusetts College of Pharmacy
Director of Pharmacy Business and Financial Services
Brigham and Women’s Hospital
Boston, MA

Faculty

Craig Beavers, PharmD
Centennial Medical Center
Lexington, KY

Leo Buckley, PharmD
Brigham and Women’s Hospital
Boston, MA

Accreditation Statements

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-21-024-L04-P).  

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CME/CE inquiries or special needs, please contact [email protected] or 610-687-3300.

Financial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim

 

Provided by AcademicCME

AcademicLogo

Thank you for pre-registering!  Now you can contribute to our content. Please email [email protected] with the question about the mechanism of action or clinical effects of SGLT-2 inhibitors that you would most like our expert faculty to address in this program.